InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Strategic Potential | Delve into InMode's opportunities for market expansion, product innovation, and diversification, balancing against regulatory risks and economic factors |
Competitive Edge | Explore InMode's innovative product portfolio and market positioning, which analysts believe could drive long-term growth despite current industry slowdown |
Financial Outlook | Analysts project EPS of 1.88 for FY2024 and 2.27 for FY2025, with price targets ranging from $29 to $33, reflecting cautious optimism amid market uncertainties |
Market Headwinds | InMode faces challenges in the aesthetic procedures market, impacting system sales and revenue growth despite its strong position in medical devices |
Metrics to compare | INMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 7.3x | −5.3x | −0.6x | |
PEG Ratio | −3.33 | 0.02 | 0.00 | |
Price / Book | 1.9x | 4.7x | 2.6x | |
Price / LTM Sales | 3.4x | 3.0x | 3.1x | |
Upside (Analyst Target) | 8.5% | 119.8% | 51.2% | |
Fair Value Upside | Unlock | −5.3% | 8.7% | Unlock |